Search

Search Constraints

You searched for: Author/Creator Lockley, Michelle

Search Results

1. 2022-RA-1310-ESGO Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. (20th October 2022)

2. 2022-RA-1443-ESGO Patient decision aids in genetic testing for women with ovarian cancer. (20th October 2022)

3. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo‐ovarian high‐grade serous carcinoma before and after neoadjuvant chemotherapy. Issue 5 (7th August 2017)

4. Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference. (September 2022)

5. Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. Issue 10 (3rd July 2013)

7. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results. (25th January 2019)

8. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results. Issue 2 (February 2019)

10. Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. Issue 2 (19th November 2019)